TABLE 4.
Demographic and pregnancy characteristics, underlying medical conditions, and SARS‐CoV‐2 infection characteristics of people with moderate‐to‐critical COVID‐19 illness in pregnancy by treatment status, SET‐NET, 18 Jurisdictions, January 25, 2020–December 31, 2020 (unweighted N = 1,732)
| COVID‐19 specific treatment b (unweighted n = 265) | Non‐COVID‐19 specific treatment (unweighted n = 157) a | No treatment reported c (unweighted n = 1,310) | |
|---|---|---|---|
| Unweighted n weighted % (95% CI) | |||
| Total a | 15.2% (12.9%–17.4%) | 7.7% (6.3%–9.1%) | 77.1% (74.6%–79.6%) |
| Age at infection, years | 265 | 157 | 1,310 |
| Median (IQR Q1‐Q3) | 31.9 (27.2‐35.3) | 30.7 (26.4‐34.8) | 29.6 (25.4‐33.6) |
| <20 | 1.8 (0.6–3.1) | 6.6 (1.3–11.9) | 3.8 (2.5–5.1) |
| 20–24 | 15.5 (7.9–22.9) | 16.2 (8.1–24.3) | 18.5 (15.6–21.4) |
| 25–29 | 21.8 (15.8–27.8) | 28.6 (20.4–36.8) | 30.5 (27.0–34.0) |
| 30–34 | 30.2 (23.2–37.2) | 24.9 (17.5–32.4) | 28.6 (25.4–31.8) |
| 35–39 | 26.1 (18.6–33.6) | 19.6 (12.3–26.8) | 14.8 (12.0–17.6) |
| 40+ | 4.7 (2.1–7.2) | 4.0 (1.5–6.6) | 3.8 (2.6–5.1) |
| Unknown | 0 | 0 | 0 |
| Race/ethnicity | 256 | 151 | 1,282 |
| Hispanic or Latina | 39.3 (31.8–46.8) | 45.6 (36.2–55.0) | 35.7 (32.3–39.0) |
| Asian, non‐Hispanic | 8.4 (4.3–12.3) | 8.1 (2.3–13.9) | 3.7 (2.0–5.4) |
| Black, non‐Hispanic | 18.7 (12.4–24.9) | 17.4 (10.7–24.1) | 14.2 (11.8–16.7) |
| White, non‐Hispanic | 30.4 (21.4–39.5) | 21.3 (13.4–29.1) | 42.7 (39.0–46.4) |
| Multiple or other d race, non‐Hispanic | 3.3 (0.7–5.8) | 7.6 (2.2–13.1) | 3.7 (2.0–5.3) |
| Unknown | 4.1 (1.4–6.8) | 4.0 (0.6–7.4) | 2.0 (1.2–2.8) |
| Health insurance | 251 | 153 | 1,273 |
| Private | 42.3 (34.0–50.7) | 42.9 (33.3–52.5) | 41.6 (37.9–45.3) |
| Medicaid | 53.6 (45.2–62.0) | 50.8 (41.4–60.2) | 54.3 (50.6–58.1) |
| Other e | 2.1 (0.8–3.5) | 5.3 (0.7–10.0) | 2.2 (1.1–3.3) |
| Self‐pay/none | 1.9 (0.7–3.2) | 0.9 (0.0–2.1) | 1.9 (1.0–2.8) |
| Unknown | 4.5 (2.0–7.1) | 1.8 (0.1–3.5) | 2.4 (1.5–3.3) |
| Underlying medical condition f | 68.7 (61.8–75.6) | 59.9 (50.5–69.2) | 57.1 (53.5–60.8) |
| Death | 2.4 (0.7–4.1) | 1.0 (0.0–2.3) | 0.5 (0.1–0.9) |
| Trimester of infection | 265 | 157 | 1,310 |
| First | 5.9 (0.0–11.8) | 8.4 (1.5–15.3) | 12.7 (10.4–15.0) |
| Second | 22.2 (15.5–28.9) | 35.0 (25.9–44.1) | 36.0 (32.4–39.6) |
| Third | 71.9 (64.0–79.8) | 56.6 (47.1–66.1) | 51.3 (47.7–55.0) |
| Timing of infection | 265 | 157 | 1,310 |
| January–June 2020 | 37.4 (30.4–44.5) | 45.0 (35.9–54.0) | 45.0 (41.5–48.5) |
| July–December 2020 | 62.6 (55.5–69.6) | 55.0 (46.0–64.1) | 55.0 (51.5–58.5) |
| Timing of treatment (days after first positive PCR test) | 238 | 133 | — |
| 0–5 | 66.8 (58.8–74.9) | 72.7 (63.2–82.3) | — |
| 6–10 | 30.4 (22.5–38.2) | 12.0 (5.5–18.4) | — |
| ≥11 | 2.8 (0.1–5.6) | 15.3 (6.7–23.8) | — |
| COVID‐19 specific treatments g | [265] | — | — |
| Remdesivir | 57.0 (48.7–65.4) | — | — |
| Dexamethasone | 45.8 (38.2–53.3) | — | — |
| Azithromycin with hydroxychloroquine | 15.4 (11.3–19.5) | — | — |
| Convalescent plasma | 12.4 (7.5–17.3) | — | — |
| Hydroxychloroquine alone | 7.3 (4.6–10.0) | — | — |
| Immunosuppressants | 1.2 (0.0–2.5) | — | — |
| Monoclonal antibodies | 1.1 (0.0–2.6) |
Participating jurisdictions included Arkansas, City of Chicago, City of Houston, Illinois (excluding Chicago), Massachusetts, Michigan, Minnesota, Missouri, Nebraska, New Hampshire, New Jersey, New York (excluding New York City), Pennsylvania (excluding Philadelphia), Puerto Rico, South Carolina, Tennessee, U.S. Virgin Islands, and Washington.
Included remdesivir, dexamethasone, azithromycin with hydroxychloroquine, convalescent plasma, hydroxychloroquine alone, immunosuppressants, and monoclonal antibodies.
Reported as not receiving treatment, missing not included in the analysis.
Other race includes Native Hawaiian or other Pacific Islander, American Indian or Alaska Native, and self‐reported as other.
Other insurance includes Indian Health Service, CHAMPUS or TRICARE; other government (federal, state, or local), or charity.
Underlying medical conditions included obesity, chronic lung disease, diabetes mellitus, chronic hypertension, cardiovascular disease, immunosuppression, renal disease, liver disease, psychological/psychiatric condition, disability, or autoimmune condition. For people with SARS‐CoV‐2 infection in the third trimester, hypertensive disorders of pregnancy and gestational diabetes were also included as underlying medical conditions.
Not mutually exclusive.